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Transition through the cell cycle involves
a series of precise events that ensure
order (DNA replication, spindle assembly,
nuclear division, and cytokinesis) and
directionality. This transition is controlled
by numerous proteins whose activities
and/or levels oscillate throughout the cell
cycle. The first oscillators discovered, the
cyclins, increase in level prior to mitosis
and fall coincidently with cytokinesis
(Murray, 2004). Cyclins interact with spe-
cific cyclin-dependent kinases (cdks) to
phosphorylate key regulators of the cell
cycle. Inhibitors of the cyclin-cdk com-
plexes were subsequently identified, one
of which is p21. Loss of these negative
regulators of the cell cycle contributes to
increased cell proliferation, which
may in turn lead to tumorigenesis.
The simultaneous discovery of
p21 as the first cdk inhibitor and as
a gene transcriptionally regulated
by the p53 tumor suppressor was
very exciting, and bridged the
function of a tumor suppressor
with the cell cycle (el-Deiry et al.,
1993; Harper et al., 1993).
The cyclin-cdk complexes are
also regulated by proteolysis via
ubiquitination, which provides
exquisite control of protein levels
and function. Ubiquitination-medi-
ated protein degradation involves
a succession of steps that cova-
lently attach multiple ubiquitin
molecules to a substrate, thereby
targeting that substrate for degradation.
First, ubiquitin is activated by the ubiqui-
tin-activating enzyme E1. Subsequently,
a ubiquitin-conjugating enzyme (called
UBC or E2) transfers the ubiquitin mole-
cule to a ubiquitin protein ligase (E3) that
covalently attaches ubiquitin to the tar-
geted substrate at specific lysine
residues. The ubiquitin protein ligases
provide the target specificity in the sys-
tem, and key E3 complexes such as the
anaphase-promoting complex (APC/C)
and Skp1/Cullin/F box protein-related
complex (SCF) regulate transition
through the cell cycle (Vodermaier,
2004). The first identified, APC/C, con-
trols degradation of securin, the protein
that maintains the cohesion of sister
chromatids prior to separation, and
numerous mitotic kinases. Additionally,
the SCF complex is responsible for
degrading G1 cyclins, the cdk inhibitors
p27Kip1 and p57Kip2, and potentially p21 in
S phase.
Although p21 is degraded by the pro-
teosome, the ubiquitination of p21 has
been controversial, since mutation of all
lysine amino acids in p21 did not stabilize
p21. Recent studies have shown, howev-
er, that ubiquitination occurs at the N ter-
minus of p21 by a unique mechanism
(Bloom et al., 2003). The discovery of a
novel mechanism for regulating p21 pro-
tein stability, described in a recent issue
of Molecular Cell, is highlighted here.
Using a two-hybrid screen, Jascur et al.
(2005) identified a novel protein, WISp39,
that binds p21 and increases p21 stability
in cell culture. Several observations indi-
cate that the interaction occurs in vivo.
First, other known p21-interacting pro-
teins, PCNA for example, were identified
in the screen. Second, endogenous p21
and endogenous WISp39 coimmunopre-
cipitate, indicating they form a complex.
WISp39 binds the N terminus of newly
synthesized p21, the region that is ubiqui-
tinated, and may in fact block ubiquitina-
tion of p21, although this has not been
shown. Moreover, WISp39 contains a
TPR (tetratricopeptide repeat) domain
that allows recruitment of the heat shock
response protein Hsp90. Hsp90 is a
chaperone responsible for correct folding,
function, and stability of various proteins
(Chiosis et al., 2004). TPR domains are
found in other Hsp90 binding proteins that
are called cochaperones. Importantly,
mutation of the TPR domain in WISp39
results in loss of interaction with Hsp90,
followed by p21 degradation, suggesting
that the trimeric complex consisting of
p21, WISp39, and Hsp90 is responsible
for correct p21 folding and protein stability.
The p53 tumor suppressor is a DNA
damage response protein that tran-
scriptionally activates numerous genes
(Vogelstein et al., 2000). The protein
products of these genes arrest the cell
cycle or induce cell death. As such,
alterations in p53 are one of the
most common events in tumorige-
nesis. The first transcriptional tar-
get of p53 identified was the cdk
inhibitor p21. That p53 transacti-
vation of p21 does not necessarily
yield increased p21 protein levels
is another important aspect of the
study described by Jascur et al.
(2005). DNA damage by ionizing
radiation results in stabilization of
wild-type p53 and subsequent
transcriptional activation of p21.
However, p21 protein levels are
not increased when WISp39 is
downmodulated with siRNA or
Hsp90 is inhibited with the drug
geldanamycin following DNA
damage.This exciting observation
suggests that p21 levels are increased
transcriptionally by p53 and at the level
of protein stability by WISp39 and Hsp90
(Figure 1). Thus, two events are required
to stabilize p21.
How important is p21 function in
tumorigenesis? Mouse embryo fibrob-
lasts from p21Cip1 null mice partially
bypass the G1/S checkpoint in response
to DNA damage, and mice lacking p21Cip1
succumb to tumor development (Lozano
and Zambetti, 2005). Additionally, onset
of spontaneous tumors in mice with a p53
mutant that retains the ability to activate
p21 occurs later than in mice with a
mutant p53 that is unable to activate p21,
suggesting that deletion or inhibition of
p21 function may contribute to tumorige-
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p21 stability: Linking chaperones to a cell cycle checkpoint
Progression through the cell cycle is regulated by numerous proteins, one of which is the cyclin-dependent kinase
inhibitor, p21. A new study identifies a novel protein complex that stabilizes p21. The stability of this complex is critical in
effecting the p53-mediated cell cycle checkpoint.
Figure 1. Regulation of p21 at multiple levels
In response to DNA damage, p53 activates transcription of
the p21 gene. An unstable p21 protein is made whose sta-
bility is increased by interactions with WISp39 and Hsp90.
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nesis (Lozano and Zambetti, 2005).
These data are offset by the knowledge
that p21 mutations in human cancers are
rare. Besides the possibility of redundant
function of other p53 targets, another
explanation for the contradictory data is
that decreases in p21 stability through
deletion or mutation of WISp39 are more
common than p21 alterations in tumor
development. The regulation of Wisp39
as a function of the cell cycle is also likely.
Counterintuitive to the role of p21 in
cell cycle arrest, p21 has also been
implicated as a positive regulator of cell
survival. For example, loss of p21 sensi-
tizes cells to undergo uncoordinated
DNA replication and death induced by
anticancer drugs (Waldman et al., 1996).
Because these cells tolerate expression
of p21 in the first place, the p21 in these
cells may not be functional in its cell
cycle-inhibiting capacity. The phosphory-
lation status of p21 differs in different cell
lines and may regulate these activities
(Li et al., 2002). Nonetheless, since p21
is overexpressed in some advanced
human tumors, downregulation of p21
protein may facilitate more efficient
chemotherapy (Seoane et al., 2002).The
newfound role of Hsp90 and WISp39 in
the stabilization of p21 certainly adds
more validity to the belief that targeting
Hsp90 could be used to treat cancer,
since inhibition of Hsp90 may reduce
p21 levels. WISp39 confers specificity on
the ability of Hsp90 to promote stability
of p21, so we could imagine that an
agent that specifically blocks WISp39
interaction with Hsp90 will serve only to
target p21 degradation without affecting
other Hsp90 targets. This scenario may
be useful in some treatment schemes
where tumor cells are dependent on p21
for survival.
Many questions remain to be
addressed. How does this complex pro-
tect p21 from degradation? How does
the trimeric complex allow p21 interac-
tion with the cyclin-cdk machinery? Does
it affect p21 phosphorylation and interac-
tions with other proteins? This study rais-
es a number of intriguing questions that
will need to be addressed in the future.
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Pioneering and painstaking work over
the last 15 years has established that
mutations in up to 11 different genes
could lead to FA (Joenje et al., 1997;
Strathdee et al., 1992). The identity of
nine of these genes is now known, and
recent studies have confirmed the genet-
ic view that they all code for components
of a single tumor suppressor pathway.
Although the primary sequences of the
FA proteins reveal very little about how
they function, we know that most of them
(FANCA, B, C, E, F, G, and L) interact to
form a nuclear complex (FA nuclear com-
plex) (reviewed in Joenje and Patel,
2001; D’Andrea and Grompe, 2003).
However, not until the publication of a
landmark paper in 2001 did we develop a
comprehensive outline of the FA path-
way (Garcia-Higuera et al., 2001). This
seminal study showed that the FA
nuclear complex is essential for the acti-
vation of a newly identified key FA pro-
tein, FANCD2. The activation step
resulted in the conjugation of one ubiqui-
tin polypeptide to a single specific lysine
residue (K561) on the FANCD2 protein.
The consequences of this modification
are to direct FANCD2 to DNA replication
or damage-induced nuclear foci. It is very
likely that at these sites, FANCD2 directs
DNA repair. Despite the evident progress
in the FA field over the last few years,
there are still many questions that need
to be resolved if we wish to gain a com-
plete molecular understanding of the FA
pathway. We will need to know more
about the precise DNA repair activity in
which the FA proteins participate. We will
need to understand the functional rele-
vance of the interactions between the
“core” FA pathway and other tumor sup-
“Dub”bing a tumor suppressor pathway
The autosomal recessive disease Fanconi anemia (FA) causes bone marrow failure and a hugely increased propensity to
develop cancer. Cells from FA patients are prone to chromosome breakage, indicating that FA gene products are required
to ensure genomic integrity. Most of the identified FA proteins are components of a nuclear complex whose principal func-
tion is to activate FANCD2 by monoubiquitination. Monoubiquitinated FANCD2 accumulates at sites of genome damage,
where it probably functions to facilitate DNA repair. A recent paper in Molecular Cell (Nijman et al., 2005) reports the identi-
fication of an enzyme that is responsible for regulating the FA pathway by deactivating FANCD2.
